Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review

Pathogens and Global Health

Volumn 110, Issue 6, 2016, Pages 247-260

  Maspi, Nahid ^a   Abdoli, Amir ^a   Ghaffarifar, Fathemeh ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Cutaneous leishmaniasis; Cytokine; Immunopathology; Immunoprotection; Leishmania

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CXCL2 CHEMOKINE; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; HELPER FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; AUTACOID; INTERLEUKIN DERIVATIVE;

CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SKIN LEISHMANIASIS; TISSUE INJURY; TREATMENT OUTCOME; IMMUNOLOGY; LEISHMANIASIS, CUTANEOUS;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKINS; LEISHMANIASIS, CUTANEOUS;

EID: 84991111430     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1080/20477724.2016.1232042     Document Type: Review

References (237)

1. J.Alvar, I.D.Vélez, C.Bern, M.Herrero, P.Desjeux, J.Cano,. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.10.1371/journal.pone.0035671
2. C.Karimkhani, V.Wanga, L.E.Coffeng, P.Naghavi, R.P.Dellavalle, M.Naghavi. Global burden of cutaneous leishmaniasis:a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(5):584–91.
3. P.Kaye, P.Scott. Leishmaniasis:complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9(8):604–15.10.1038/nrmicro2608
4. D.Sacks, S.Kamhawi. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol. 2001;55:453–83.10.1146/annurev.micro.55.1.453
5. P.Scott, F.O.Novais,. Cutaneous leishmaniasis:immune responses in protection and pathogenesis. Nat Rev Immunol. 2016; 16(9):581–92.
6. M.S.Bailey, D.N.Lockwood. Cutaneous leishmaniasis. Clin Dermatol. 2007;25(2):203–11.10.1016/j.clindermatol.2006.05.008
7. E.von Stebut, J.M.Ehrchen, Y.Belkaid, S.L.Kostka, K.Mölle, J.Knop,. Interleukin 1α promotes Th(1) differentiation and inhibits disease progression in Leishmania major – susceptible BALB/c mice. J Exp Med. 2003;198(2):191–99.10.1084/jem.20030159
8. D.Sacks, N.Noben-Trauth. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845–58.10.1038/nri933
9. S.Gordon. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.10.1038/nri978
10. P.Kropf, J.M.Fuentes, E.Fahnrich, L.Arpa, S.Herath, V.Weber,. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J. 2005;19(8):1000–02.
11. S.Nylén, L.Eidsmo. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol. 2012;34(12):551–61.10.1111/pim.12007
12. P.Martin, S.J.Leibovich. Inflammatory cells during wound repair:the good, the bad and the ugly. Trend Cell Biol. 2005;15(11):599–607.10.1016/j.tcb.2005.09.002
13. S.A.Eming, T.Krieg, J.M.Davidson. Inflammation in wound repair:molecular and cellular mechanisms. J Invest Dermatol. 2007;127(3):514–25.10.1038/sj.jid.5700701
14. L.A.Borthwick, T.A.Wynn, A.J.Fisher. Cytokine mediated tissue fibrosis. BBA-Mol Basis Dis. 2013;1832(7):1049–60.10.1016/j.bbadis.2012.09.014
15. M.Pasparakis, I.Haase, F.O.Nestle. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14(5):289–301.10.1038/nri3646
16. J.E.Allen, T.A.Wynn. Evolution of Th2 Immunity:a rapid repair response to tissue destructive pathogens. PLoS Pathogens. 2011;7(5):e1002003.10.1371/journal.ppat.1002003
17. W.C.Gause, T.A.Wynn, J.E.Allen. Type 2 immunity and wound healing:evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13(8):607–14.10.1038/nri3476
18. R.A.Seder, P.A.Darrah, M.Roederer. T-cell quality in memory and protection:implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–58.10.1038/nri2274
19. W.Wu, L.Huang, S.Mendez. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur J Immunol. 2010;40(9):2517–27.10.1002/eji.201040484
20. J.R.Schoenborn, C.B.Wilson. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.10.1016/S0065-2776(07)96002-2
21. U.Sharma, S.Singh. Immunobiology of leishmaniasis. Indian J Exp Biol. 2009;47(6):412–23.
22. J.Alexander, A.R.Satoskar, D.G.Russell. Leishmania species:models of intracellular parasitism. J Cell Sci. 1999;112(18):2993–3002.
23. R.O.Pinheiro, B.Rossi-Bergmann. Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice. Mem Inst Oswaldo Cruz. 2007;102(1):79–82.10.1590/S0074-02762007000100013
24. F.Y.Liew, X.Q.Wei, L.Proudfoot. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci. 1997;352(1359):1311–15.10.1098/rstb.1997.0115
25. P.Wilhelm, U.Ritter, S.Labbow, N.Donhauser, M.Rollinghoff, C.Bogdan,. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking tnf. J Immunol. 2001;166(6):4012–19.10.4049/jimmunol.166.6.4012
26. C.M.Theodos, L.Povinelli, R.Molina, B.Sherry, R.G.Titus. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immune. 1991;59(8):2839–42.
27. I.Garcia, Y.Miyazaki, K.Araki, M.Araki, R.Lucas, G.E.Grau,. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol. 1995;25(8):2401–07.10.1002/(ISSN)1521-4141
28. F.Y.Liew, Y.Li, S.Millott. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol. 1990;145(12):4306–10.
29. A.Gaafar, B.Veress, H.Permin, A.Kharazmi, T.G.Theander, A.M.El Hassan. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol. 1999;91(3):314–20.10.1006/clim.1999.4705
30. M.M.Pompeu, C.Brodskyn, M.J.Teixeira, J.Clarencio, J.Van Weyenberg, I.C.Coelho,. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect Immun. 2001;69(12):7453–60.10.1128/IAI.69.12.7453-7460.2001
31. L.R.V.Antonelli, W.O.Dutra, R.P.Almeida, O.Bacellar, K.J.Gollob. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol. 2004;136(2):341–8.10.1111/cei.2004.136.issue-2
32. F.Oliveira, A.Bafica, A.B.Rosato, C.B.Favali, J.M.Costa, V.Cafe,. Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis. Am J Trop Med Hyg. 2011;85(1):70–3.10.4269/ajtmh.2011.10-0680
33. A.D'Oliveira JuniorJr., P.Machado, O.Bacellar, L.H.Cheng, R.P.Almeida, E.M.Carvalho. Evaluation of IFN-gamma and TNF-alpha as immunological markers of clinical outcome in cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2002;35(1):7–10.10.1590/S0037-86822002000100002
34. O.Bacellar, H.Lessa, A.Schriefer, P.Machado, A.Ribeiro de Jesus, W.O.Dutra,. Up-Regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70(12):6734–40.10.1128/IAI.70.12.6734-6740.2002
35. L.R.Antonelli, W.O.Dutra, R.P.Almeida, O.Bacellar, E.M.Carvalho, K.J.Gollob. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. 2005;101(2):226–30.10.1016/j.imlet.2005.06.004
36. F.Ivonise, A.Cibele, B.Olívia, B.A.Clarissa, P.C.Lucas, P.A.Roque,. Epidemiologic and Immunologic Findings for the Subclinical Form of Leishmania braziliensis Infection. Clin Infect Dis. 2002;34(11):e54–e8.
37. E.M.Carvalho, W.D.Johnson, E.Barreto, P.D.Marsden, J.L.Costa, S.Reed,. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol. 1985;135(6):4144–48.
38. A.Ribeiro-de-Jesus, R.P.Almeida, H.Lessa, O.Bacellar, E.M.Carvalho. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998;31(1):143–8.10.1590/S0100-879X1998000100020
39. W.N.Oliveira, L.E.Ribeiro, A.Schrieffer, P.Machado, E.M.Carvalho, O.Bacellar. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine. 2014;66(2):127–32.10.1016/j.cyto.2013.12.016
40. M.L.Güler, J.D.Gorham, C.-S.Hsieh, A.J.Mackey, R.G.Steen, W.F.Dietrich,. Genetic susceptibility to leishmania:IL-12 responsiveness in TH1 cell development. Science. 1996;271(5251):984–7.10.1126/science.271.5251.984
41. C.S.Constantinescu, B.D.Hondowicz, M.M.Elloso, M.Wysocka, G.Trinchieri, P.Scott. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol. 1998;28(7):2227–33.10.1002/(ISSN)1521-4141
42. J.P.Sypek, C.L.Chung, S.E.Mayor, J.M.Subramanyam, S.J.Goldman, D.S.Sieburth,. Resolution of cutaneous leishmaniasis:interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993;177(6):1797–1802.10.1084/jem.177.6.1797
43. E.M.Palmer, L.Farrokh-Siar, J.Maguire van Seventer, G.A.Van Seventer,. IL-12 Decreases activation-induced cell death in human naive Th Cells costimulated by intercellular adhesion molecule-1. I. IL-12 alters caspase processing and inhibits enzyme function. J Immunol. 2001;167(2):749–58.10.4049/jimmunol.167.2.749
44. A.C.Mullen, F.A.High, A.S.Hutchins, H.W.Lee, A.V.Villarino, D.M.Livingston,. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001;292(5523):1907–10.10.1126/science.1059835
45. M.K.Gately, L.M.Renzetti, J.Magram, A.S.Stern, L.Adorini, U.Gubler,. The interleukin-12/interleukin-12-receptor system:role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495–521.10.1146/annurev.immunol.16.1.495
46. X.Mal, G.Trinchieri,. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 2001;79:55–92.10.1016/S0065-2776(01)79002-5
47. D.A.Vignali, V.K.Kuchroo. IL-12 family cytokines:immunological playmakers. Nat Immunol. 2012;13(8):722–8.10.1038/ni.2366
48. K.Gee, C.Guzzo, N.F.Che Mat, W.Ma, A.Kumar. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8(1):40–52.10.2174/187152809787582507
49. A.Y.Park, B.Hondowicz, M.Kopf, P.Scott. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol. 2002;168(11):5771–77.10.4049/jimmunol.168.11.5771
50. F.Mattner, J.Magram, J.Ferrante, P.Launois, K.Padova, R.Behin,. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol. 1996;26(7):1553–59.10.1002/(ISSN)1521-4141
51. M.W.L.Teng, E.P.Bowman, J.J.McElwee, M.J.Smyth, J.-L.Casanova, A.M.Cooper,. IL-12 and IL-23 cytokines:from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–29.10.1038/nm.3895
52. C.Parham, M.Chirica, J.Timans, E.Vaisberg, M.Travis, J.Cheung,. A receptor for the Heterodimeric cytokine IL-23 Is Composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–708.10.4049/jimmunol.168.11.5699
53. L.Afonso, T.M.Scharton, L.Q.Vieira, M.Wysocka, G.Trinchieri, P.Scott. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 1994;263(5144):235–7.10.1126/science.7904381
54. R.T.Kenney, D.L.Sacks, J.P.Sypek, L.Vilela, A.A.Gam, K.Evans-Davis. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 1999;163(8):4481–8.
55. N.Maspi, F.Ghaffarifar, Z.Sharifi, A.Dalimi,. Co-delivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice. Parasit Immunol. 2016;38(4):228–35.
56. F.P.Heinzel, D.S.Schoenhaut, R.M.Rerko, L.E.Rosser, M.K.Gately. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med. 1993;177(5):1505–09.10.1084/jem.177.5.1505
57. T.R.Malek. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–79.10.1146/annurev.immunol.26.021607.090357
58. R.Setoguchi, S.Hori, T.Takahashi, S.Sakaguchi. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723–35.10.1084/jem.20041982
59. O.Boyman, J.Sprent. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90.
60. S.L.Gaffen, K.D.Liu. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28(3):109–23.10.1016/j.cyto.2004.06.010
61. K.A.Smith. Interleukin-2:inception, impact, and implications. Science. 1988;240(4856):1169–76.10.1126/science.3131876
62. B.H.Nelson. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):3983–8.10.4049/jimmunol.172.7.3983
63. T.R.Malek, A.Yu, V.Vincek, P.Scibelli, L.Kong. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice:implications for the nonredundant function of IL-2. Immunity. 2002;17(2):167–78.10.1016/S1074-7613(02)00367-9
64. T.R.Malek, B.O.Porter, E.K.Codias, P.Scibelli, A.Yu. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol. 2000;164(6):2905–14.10.4049/jimmunol.164.6.2905
65. T.R.Malek. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74(6):961–5.10.1189/jlb.0603272
66. X.Wang, T.Mosmann. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med. 2001;194(8):1069–80.10.1084/jem.194.8.1069
67. V.Mashayekhi Goyonlo, H.Elnour, K.Nordlind. Interleukin-2 expression in lupoid and usual types of old world cutaneous leishmaniasis. Iran Red Crescent Med J. 2014;16(11):e5410.
68. P.R.Oliveira, H.Dessein, A.Romano, S.Cabantous, M.E.de Brito, F.Santoro,. IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis. J Immunol. 2015;194(6):2664–72.10.4049/jimmunol.1402047
69. T.T.Espir, L.de Paula Figueira, M.de Farias Naiff, A.G.da Costa, M.Ramalho-Ortigão, A.Malheiro,. The role of inflammatory, anti-inflammatory, and regulatory cytokines in patients infected with cutaneous leishmaniasis in amazonas state, Brazil. J Immunol Res. 2014;2014:10. doi:10.1155/2014/481750
70. S.Divanovic, A.Trompette, J.I.Ashworth, M.B.Rao, C.L.Karp,. Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis. 2011;5(9). doi:10.1371/journal.pntd.0001316.
71. G.Le Gros, S.Z.Ben-Sasson, R.Seder, F.Finkelman, W.Paul. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro:IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med. 1990;172(3):921–9.10.1084/jem.172.3.921
72. M.Kondo, T.Takeshita, N.Ishii, M.Nakamura, S.Watanabe, K.Arai,. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 1993;262(5141):1874–77.10.1126/science.8266076
73. S.M.Russell, A.D.Keegan, N.Harada, Y.Nakamura, M.Noguchi, P.Leland,. Interleukin-2 receptor gamma chain:a functional component of the interleukin-4 receptor. Science. 1993;262(5141):1880–3.10.1126/science.8266078
74. F.P.Heinzel, R.M.Rerko, F.Hatam, R.M.Locksley. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol. 1993;150(9):3924–31.
75. R.N.Apte, E.Voronov. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222(1):222–41.10.1111/j.1600-065X.2008.00615.x
76. P.E.Auron. The interleukin 1 receptor:ligand interactions and signal transduction. Cytokine Growth Factor Rev. 1998;9(3–4):221–37.10.1016/S1359-6101(98)00018-5
77. A.Mantovani, M.Muzio, P.Ghezzi, C.Colotta, M.Introna. Regulation of inhibitory pathways of the interleukin-1 system. Ann N Y Acad Sci. 1998;840:338–51.10.1111/nyas.1998.840.issue-1
78. E.Stylianou, J.Saklatvala. Interleukin-1. Int J Biochem Cell Biol. 1998;30(10):1075–79.10.1016/S1357-2725(98)00081-8
79. M.Charmoy, B.P.Hurrell, A.Romano, S.H.Lee, F.Ribeiro-Gomes, N.Riteau,. The Nlrp3 inflammasome, IL-1beta, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice. Eur J Immunol. 2016;46(4):897–911.10.1002/eji.201546015
80. Y.Chung, S.H.Chang, G.J.Martinez, X.O.Yang, R.Nurieva, H.S.Kang,. Critical regulation of early Th17 cell differentiation by IL-1 signaling. Immunity. 2009;30(4):576–87.10.1016/j.immuni.2009.02.007
81. D.S.Lima-Junior, D.L.Costa, V.Carregaro, L.D.Cunha, A.L.Silva, T.W.Mineo,. Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med. 2013;19(7):909–15.10.1038/nm.3221
82. K.A.Pape, A.Khoruts, A.Mondino, M.K.Jenkins. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997;159(2):591–8.
83. S.L.Kostka, J.Knop, A.Konur, M.C.Udey, E.von Stebut. Distinct roles for IL-1 receptor type I Signaling in early versus established Leishmania major infections. J Invest Dermatol. 2006;126(7):1582–9.10.1038/sj.jid.5700309
84. P.Gurung, R.Karki, P.Vogel, M.Watanabe, M.Bix, M.Lamkanfi,. An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. J Clin Invest. 2015;125(3):1329–38.10.1172/JCI79526
85. C.Gonzalez-Lombana, C.Gimblet, O.Bacellar, W.W.Oliveira, S.Passos, L.P.Carvalho,. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013;9(3):e1003243.10.1371/journal.ppat.1003243
86. E.Voronov, S.Dotan, L.Gayvoronsky, R.M.White, I.Cohen, Y.Krelin,. IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol. 2010;22(4):245–57.10.1093/intimm/dxq006
87. K.Kautz-Neu, S.L.Kostka, S.Dinges, Y.Iwakura, M.C.Udey, E.von Stebut. IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Exp Dermatol. 2011;20(1):76–8.10.1111/j.1600-0625.2010.01172.x
88. T.Ikejima, S.Okusawa, P.Ghezzi, J.W.Van der Meer, C.A.Dinarello. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis. 1990;162(1):215–23.10.1093/infdis/162.1.215
89. H.Tsutsui, K.Adachi, E.Seki, K.Nakanishi. Cytokine-induced inflammatory liver injuries. Curr Mol Med. 2003;3(6):545–59.10.2174/1566524033479618
90. C.A.Dinarello, G.Fantuzzi. Interleukin‐18 and host defense against infection. J Infect Dis. 2003;187(s2):S370–84.10.1086/jid.2003.187.issue-s2
91. X.Q.Wei, B.P.Leung, W.Niedbala, D.Piedrafita, G.J.Feng, M.Sweet,. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol. 1999;163(5):2821–8.
92. G.M.Monteforte, K.Takeda, M.Rodriguez-Sosa, S.Akira, J.R.David, A.R.Satoskar. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol. 2000;164(11):5890–3.10.4049/jimmunol.164.11.5890
93. D.Xu, V.Trajkovic, D.Hunter, B.P.Leung, K.Schulz, J.A.Gracie,. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol. 2000;30(11):3147–56.10.1002/(ISSN)1521-4141
94. P.Gurung, T.-D.Kanneganti. Novel role for inflammasome-dependent IL-18 in promoting Th2 responses during Leishmania infections (IRC7P.420). J Immunol. 2015;194(1 Supplement):128.
95. J.P.Lodolce, P.R.Burkett, R.M.Koka, D.L.Boone, A.Ma. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002;13(6):429–39.10.1016/S1359-6101(02)00029-1
96. K.H.Grabstein, J.Eisenman, K.Shanebeck, C.Rauch, S.Srinivasan, V.Fung,. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264(5161):965–8.10.1126/science.8178155
97. T.A.Fehniger, M.A.Caligiuri. Interleukin 15:biology and relevance to human disease. Blood. 2001;97(1):14–32.10.1182/blood.V97.1.14
98. D.Jullien, P.A.Sieling, K.Uyemura, N.D.Mar, T.H.Rea, R.L.Modlin. IL-15, an immunomodulator of T cell responses in intracellular infection. J Immunol. 1997;158(2):800–06.
99. W.E.Carson, M.E.Ross, R.A.Baiocchi, M.J.Marien, N.Boiani, K.Grabstein,. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995;96(6):2578–82.10.1172/JCI118321
100. T.A.Waldmann, Y.Tagaya. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19–49.10.1146/annurev.immunol.17.1.19
101. B.R.Lauwerys, N.Garot, J.-C.Renauld, F.A.Houssiau. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165(4):1847–53.10.4049/jimmunol.165.4.1847
102. M.J.Loza, L.Zamai, L.Azzoni, E.Rosati, B.Perussia. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002;99(4):1273–81.10.1182/blood.V99.4.1273
103. P.D’Agostino, S.Milano, F.Arcoleo, G.Di Bella, M.La Rosa, V.Ferlazzo,. Interleukin-15, as interferon-gamma, induces the killing of leishmania infantum in phorbol-myristate-acetate-activated macrophages increasing interleukin-12. Scand J Immunol. 2004;60(6):609–14.10.1111/sji.2004.60.issue-6
104. S.Milano, G.Bella, P.D’agostino, C.Barbera, R.Caruso, M.Rosa,. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol. 2002;127(2):360–5.10.1046/j.1365-2249.2002.01749.x
105. M.E.Hammond, G.R.Lapointe, P.H.Feucht, S.Hilt, C.A.Gallegos, C.A.Gordon,. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995;155(3):1428–33.
106. R.Badolato, D.L.Sacks, D.Savoia, T.Musso. Leishmania major:infection of human monocytes induces expression of IL-8 and MCAF. Exp Parasitol. 1996;82(1):21–6.10.1006/expr.1996.0003
107. K.Müller, G.Zandbergen, B.Hansen, H.Laufs, N.Jahnke, W.Solbach,. Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med Microbiol Immunol. 2001;190(1–2):73–6.10.1007/s004300100084
108. A.B.Guimaraes-Costa, M.T.Nascimento, G.S.Froment, R.P.Soares, F.N.Morgado, F.Conceicao-Silva,. Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci USA. 2009;106(16):6748–53.10.1073/pnas.0900226106
109. N.C.Rochael, A.B.Guimarães-Costa, M.T.Nascimento, T.S.DeSouza-Vieira, M.P.Oliveira, L.F.Garcia e Souza,. Classical ROS-dependent and early/rapid ROS-independent release of Neutrophil Extracellular Traps triggered by Leishmania parasites. Sci Rep. 2015;5:18302.10.1038/srep18302
110. F.O.Novais, R.C.Santiago, A.Bafica, R.Khouri, L.Afonso, V.M.Borges,. Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J Immunol. 2009;183(12):8088–98.10.4049/jimmunol.0803720
111. É.CarmoÉVdS, S.Katz, C.L.Barbiéri. Neutrophils reduce the parasite burden in Leishmania (Leishmania) amazonensis-infected macrophages. PLoS ONE. 2010;5(11):e13815.10.1371/journal.pone.0013815
112. N.C.Peters, J.G.Egen, N.Secundino, A.Debrabant, N.Kimblin, S.Kamhawi,. In vivo imaging reveals an essential role for neutrophils in Leishmaniasis transmitted by sand flies. Science. 2008;321(5891):970–4.10.1126/science.1159194
113. Y.Belkaid, S.Mendez, R.Lira, N.Kadambi, G.Milon, D.Sacks. A natural model of Leishmania major infection reveals a prolonged ‘silent’ phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. 2000;165(2):969–77.10.4049/jimmunol.165.2.969
114. H.Laufs, K.Muller, J.Fleischer, N.Reiling, N.Jahnke, J.C.Jensenius,. Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect Immun. 2002;70(2):826–35.10.1128/IAI.70.2.826-835.2002
115. P.Scapini, J.A.Lapinet-Vera, S.Gasperini, F.Calzetti, F.Bazzoni, M.A.Cassatella. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195–203.10.1034/j.1600-065X.2000.17706.x
116. M.Charmoy, S.Brunner-Agten, D.Aebischer, F.Auderset, P.Launois, G.Milon,. Neutrophil-Derived CCL3 Is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice. PLoS Pathog. 2010;6(2):e1000755.10.1371/journal.ppat.1000755
117. F.L.Ribeiro-Gomes, D.Sacks. The influence of early neutrophil-Leishmania interactions on the host immune response to infection. Front Cell Infect Microbiol. 2012;2:59. doi:10.3389/fcimb.2012.00059
118. F.L.Ribeiro-Gomes, A.Romano, S.Lee, E.Roffê, N.C.Peters, A.Debrabant,. Apoptotic cell clearance of Leishmania major-infected neutrophils by dendritic cells inhibits CD8(+) T-cell priming in vitro by Mer tyrosine kinase-dependent signaling. Cell Death Dis. 2015;6:e2018.10.1038/cddis.2015.351
119. G.Van Zandbergen, M.Klinger, A.Mueller, S.Dannenberg, A.Gebert, W.Solbach,. Cutting edge:neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol. 2004;173(11):6521–5.10.4049/jimmunol.173.11.6521
120. J.K.Kolls, A.Lindén. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.10.1016/j.immuni.2004.08.018
121. M.J.McGeachy, D.J.Cua. Th17 cell differentiation:the long and winding road. Immunity. 2008;28(4):445–53.10.1016/j.immuni.2008.03.001
122. M.J.McGeachy, K.S.Bak-Jensen, Y.Chen, C.M.Tato, W.Blumenschein, T.McClanahan,. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8(12):1390–7.10.1038/ni1539
123. H.Park, Z.Li, X.O.Yang, S.H.Chang, R.Nurieva, Y.H.Wang,. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.10.1038/ni1261
124. L.E.Harrington, R.D.Hatton, P.R.Mangan, H.Turner, T.L.Murphy, K.M.Murphy,. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.10.1038/ni1254
125. C.Sutton, C.Brereton, B.Keogh, K.H.G.Mills, E.C.Lavelle. A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203(7):1685–91.10.1084/jem.20060285
126. F.Annunziato, L.Cosmi, V.Santarlasci, L.Maggi, F.Liotta, B.Mazzinghi,. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–61.10.1084/jem.20070663
127. D.C.Newcomb, W.Zhou, M.L.Moore, K.Goleniewska, G.K.Hershey, J.K.Kolls,. A functional IL-13 receptor Is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182(9):5317–21.10.4049/jimmunol.0803868
128. M.Batten, J.Li, S.Yi, N.M.Kljavin, D.M.Danilenko, S.Lucas,. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7(9):929–36.10.1038/ni1375
129. J.S.Stumhofer, A.Laurence, E.H.Wilson, E.Huang, C.M.Tato, L.M.Johnson,. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7(9):937–45.10.1038/ni1376
130. M.A.Kleinschek, A.M.Owyang, B.Joyce-Shaikh, C.L.Langrish, Y.Chen, D.M.Gorman,. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204(1):161–70.10.1084/jem.20061738
131. S.Lopez Kostka, S.Dinges, K.Griewank, Y.Iwakura, M.C.Udey, E.Von Stebut. IL-17 promotes progression of cutaneous Leishmaniasis in susceptible mice. J Immunol. 2009;182(5):3039–46.10.4049/jimmunol.0713598
132. O.Bacellar, D.Faria, M.Nascimento, T.M.Cardoso, K.J.Gollob, W.O.Dutra,. Interleukin 17 production among patients with American cutaneous Leishmaniasis. J Infect Dis. 2009;200(1):75–8.10.1086/599173
133. N.C.Peters, S.Bertholet, P.G.Lawyer, M.Charmoy, A.Romano, F.L.Ribeiro-Gomes,. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid a stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice. J Immunol. 2012;189(10):4832–41.10.4049/jimmunol.1201676
134. A.Banerjee, P.Bhattacharya, A.B.Joshi, N.Ismail, R.Dey, H.L.Nakhasi. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol. 2016. doi:10.1016/j.cellimm.2016.07.004
135. R.Sabat, W.Ouyang, K.Wolk. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21–38.
136. S.Rutz, C.Eidenschenk, W.Ouyang. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252(1):116–32.10.1111/imr.12027
137. C.Gimblet, M.A.Loesche, L.Carvalho, E.M.Carvalho, E.A.Grice, D.Artis,. IL-22 protects against tissue damage during cutaneous Leishmaniasis. PLOS ONE. 2015;10(8):e0134698.10.1371/journal.pone.0134698
138. H.Z.Hezarjaribi, F.Ghaffarifar, A.Dalimi, Z.Sharifi. Evaluation of protective effect of IL-22 and IL-12 on cutaneous leishmaniasis in BALB/c mice. Asian Pacific J Trop Med. 2014;7(12):940–5.10.1016/S1995-7645(14)60166-8
139. H.Z.Hezarjaribi, F.Ghaffarifar, A.Dalimi, Z.Sharifi, O.Jorjani. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice. Exp Parasitol. 2013;134(3):341–8.10.1016/j.exppara.2013.03.012
140. S.Brosch, K.Dietze-Schwonberg, S.Lopez Kostka, B.Lorenz, S.Haak, B.Becher,. Disease control in cutaneous Leishmaniasis is independent of IL-22. J Invest Dermatol. 2015;135(1):308–11.10.1038/jid.2014.282
141. J.Scheller, A.Chalaris, D.Schmidt-Arras, S.Rose-John. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA). Mol Cell Res. 2011;1813(5):878–88.
142. R.G.Titus, G.K.DeKrey, R.V.Morris, M.B.P.Soares. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease. Infect Immune. 2001;69(8):5189–92.10.1128/IAI.69.8.5189-5192.2001
143. B.Saha, A.Saini, R.Germond, P.J.Perrin, D.M.Harlan, T.A.Davis. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol. 1999;29(7):2319–29.10.1002/(ISSN)1521-4141
144. N.H.Moskowitz, D.R.Brown, S.L.Reiner. Efficient immunity against Leishmania major in the absence of interleukin-6. Infect Immun. 1997;65(6):2448–50.
145. D.E.Hatzigeorgiou, S.He, J.Sobel, K.H.Grabstein, A.Hafner, J.Ho. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J Immunol. 1993;151(7):3682–92.
146. R.A.Kastelein, C.A.Hunter, D.J.Cua. Discovery and biology of IL-23 and IL-27:related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221–42.10.1146/annurev.immunol.22.012703.104758
147. C.A.Hunter, A.Villarino, D.Artis, P.Scott. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev. 2004;202(1):106–14.10.1111/imr.2004.202.issue-1
148. A.V.Villarino, E.Huang, C.A.Hunter. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.10.4049/jimmunol.173.2.715
149. T.Yoshimura, A.Takeda, S.Hamano, Y.Miyazaki, I.Kinjyo, T.Ishibashi,. Two-sided roles of IL-27:induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol. 2006;177(8):5377–85.
150. G.Murugaiyan, A.Mittal, R.Lopez-Diego, L.M.Maier, D.E.Anderson, H.L.Weiner. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol. 2009;183(4):2435–43.
151. H.Yoshida, S.Hamano, G.Senaldi, T.Covey, R.Faggioni, S.Mu,. WSX-1 Is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 2001;15(4):569–78.10.1016/S1074-7613(01)00206-0
152. D.Artis, L.M.Johnson, K.Joyce, C.Saris, A.Villarino, C.A.Hunter,. Cutting edge:early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol. 2004;172(8):4672–5.10.4049/jimmunol.172.8.4672
153. Y.Belkaid, C.A.Piccirillo, S.Mendez, E.M.Shevach, D.L.Sacks. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7.10.1038/nature01152
154. K.W.Moore, R.de Waal Malefyt, R.L.Coffman, A.O’Garra. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.10.1146/annurev.immunol.19.1.683
155. M.Saraiva, A.O’Garra. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–81.10.1038/nri2711
156. K.J.Maloy, F.Powrie. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2(9):816–22.10.1038/ni0901-816
157. A.O’Garra, P.Vieira. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425–8.10.1038/nri2097
158. G.Trinchieri. Interleukin-10 production by effector T cells:Th1 cells show self control. J Exp Med. 2007;204(2):239–243.10.1084/jem.20070104
159. A.O’Garra, P.Vieira. TH1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425–8.10.1038/nri2097
160. Y.Belkaid, K.F.Hoffmann, S.Mendez, S.Kamhawi, M.C.Udey, T.A.Wynn,. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of Anti–IL-10 receptor antibody for sterile cure. J Exp Med. 2001;194(10):1497–1506.10.1084/jem.194.10.1497
161. C.F.Anderson, S.Mendez, D.L.Sacks. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol. 2005;174(5):2934–41.10.4049/jimmunol.174.5.2934
162. L.R.Castellano, D.C.Filho, L.Argiro, H.Dessein, A.Prata, A.Dessein,. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol. 2009;70(6):383–390.10.1016/j.humimm.2009.01.007
163. A.Salhi, V.RodriguesJr, F.Santoro, H.Dessein, A.Romano, L.R.Castellano,. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008;180(9):6139–48.10.4049/jimmunol.180.9.6139
164. L.U.Buxbaum, P.Scott. Interleukin 10- and Fcγ receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immune. 2005;73(4):2101–08.10.1128/IAI.73.4.2101-2108.2005
165. C.B.Stober, U.G.Lange, M.T.Roberts, A.Alcami, J.M.Blackwell. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol. 2005;175(4):2517–24.10.4049/jimmunol.175.4.2517
166. P.A.Darrah, S.T.Hegde, D.T.Patel, R.W.Lindsay, L.Chen, M.Roederer,. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med. 2010;207(7):1421–33.10.1084/jem.20092532
167. A.Gomes-Silva, R.De Cássia Bittar, R.Dos Santos Nogueira, V.S.Amato, M.Da Silva Mattos, M.P.Oliveira-Neto,. Can interferon-γ and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol. 2007;149(3):440–4.10.1111/j.1365-2249.2007.03436.x
168. S.Sakaguchi. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.10.1146/annurev.immunol.21.120601.141122
169. K.Nakamura, A.Kitani, W.Strober. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629–44.10.1084/jem.194.5.629
170. Y.Y.Wan, R.A.Flavell. ‘Yin-Yang’ functions of TGF-β and Tregs in immune regulation. Immunol Rev. 2007;220:199–213.10.1111/imr.2007.220.issue-1
171. E.M.Shevach. CD4+ CD25+ suppressor T cells:more questions than answers. Nat Rev Immunol. 2002;2(6):389–400.
172. P.L.Vieira, J.R.Christensen, S.Minaee, E.J.O’Neill, F.J.Barrat, A.Boonstra,. IL-10-secreting regulatory T cells do not express foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004;172(10):5986–93.10.4049/jimmunol.172.10.5986
173. M.G.Roncarolo, R.Bacchetta, C.Bordignon, S.Narula, M.K.Levings. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79.10.1034/j.1600-065X.2001.1820105.x
174. M.Stassen, S.Fondel, T.Bopp, C.Richter, C.Müller, J.Kubach,. Human CD25+ regulatory T cells:two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol. 2004;34(5):1303–11.10.1002/(ISSN)1521-4141
175. H.L.Weiner. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207–14.10.1034/j.1600-065X.2001.1820117.x
176. C.F.Anderson, M.Oukka, V.J.Kuchroo, D.Sacks. CD4(+)CD25(−)Foxp3(−) Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med. 2007;204(2):285–97.10.1084/jem.20061886
177. L.R.Castellano, L.Argiro, H.Dessein, A.Dessein, M.V.da Silva, D.Correia,. Potential use of interleukin-10 blockade as a therapeutic strategy in human cutaneous Leishmaniasis. J Immunol Res. 2015;2015:5, Article ID 152741. doi:10.1155/2015/152741
178. M.Kopf, G.Gros, M.Bachmann, M.Lamers, H.Bluethmann, G.Köhler. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993;362(6417):245–8.10.1038/362245a0
179. J.Zamorano, M.Rivas, G.Perez. Interleukin-4:a multifunctional cytokine. Immunologia. 2003;22(2):215–24.
180. W.E.Paul. Interleukin-4:a prototypic immunoregulatory lymphokine. Blood. 1991;77(9):1859–70.
181. S.Gordon. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.10.1038/nri978
182. S.J.Szabo, A.S.Dighe, U.Gubler, K.M.Murphy. Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med. 1997;185(5):817–24.10.1084/jem.185.5.817
183. C.A.Lazarski, J.Ford, S.D.Katzman, A.F.Rosenberg, D.J.Fowell. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS ONE. 2013;8(8):e71949.10.1371/journal.pone.0071949
184. S.Gordon, F.O.Martinez. Alternative activation of macrophages:mechanism and functions. Immunity. 2010;32(5):593–604.10.1016/j.immuni.2010.05.007
185. M.Munder, K.Eichmann, M.Modolell. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance:competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160(11):5347–54.
186. M.Munder, K.Eichmann, J.M.Moran, F.Centeno, G.Soler, M.Modolell. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol. 1999;163(7):3771–7.
187. M.Hesse, M.Modolell, A.C.La Flamme, M.Schito, J.M.Fuentes, A.W.Cheever,. Differential regulation of nitric oxide synthase-2 and arginase-1 by Type 1/Type 2 cytokines in vivo:granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167(11):6533–44.10.4049/jimmunol.167.11.6533
188. M.Kopf, F.Brombacher, G.Kohler, G.Kienzle, K.H.Widmann, K.Lefrang,. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med. 1996;184(3):1127–36.10.1084/jem.184.3.1127
189. M.Radwanska, A.J.Cutler, J.C.Hoving, S.Magez, C.Holscher, A.Bohms,. Deletion of IL-4ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog. 2007;3(5):e68.10.1371/journal.ppat.0030068
190. M.D.Sadick, F.P.Heinzel, B.J.Holaday, R.T.Pu, R.S.Dawkins, R.M.Locksley. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med. 1990;171(1):115–27.10.1084/jem.171.1.115
191. F.P.Heinzel, M.D.Sadick, B.J.Holaday, R.L.Coffman, R.M.Locksley. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989;169(1):59–72.10.1084/jem.169.1.59
192. N.Noben-Trauth, W.E.Paul, D.L.Sacks. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol. 1999;162(10):6132–6140.
193. N.Noben-Trauth, P.Kropf, I.Muller. Susceptibility to Leishmania major Infection in Interleukin-4-deficient mice. Science. 1996;271(5251):987–90.10.1126/science.271.5251.987
194. J.Alexander, F.Brombacher, H.A.McGachy, A.N.McKenzie, W.Walker, K.C.Carter. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol. 2002;32(10):2923–33.10.1002/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E
195. P.Scott, A.Eaton, W.C.Gause, X.di Zhou, B.Hondowicz. Early IL-4 production does not predict susceptibility to Leishmania major. Exp Parasitol. 1996;84(2):178–87.10.1006/expr.1996.0103
196. P.Kropf, S.Herath, V.Weber, M.Modolell, I.Muller. Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite Immunol. 2003;25(8–9):439–47.10.1111/pim.2003.25.issue-8-9
197. P.Chomarat, J.Banchereau. Interleukin-4 and interleukin-13:their similarities and discrepancies. Int Rev Immunol. 1998;17(1–4):1–52.10.3109/08830189809084486
198. M.R.de WaalMalefyt R, C.G.Figdor, R.Huijbens, S.Mohan-Peterson, B.Bennett, J.Culpepper,. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol. 1993;151(11):6370–81.
199. T.M.Doherty, R.Kastelein, S.Menon, S.Andrade, R.L.Coffman. Modulation of murine macrophage function by IL-13. J Immunol. 1993;151(12):7151–60.
200. I.P.Oswald, R.T.Gazzinelli, A.Sher, S.L.James. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immunol. 1992;148(11):3578–82.
201. T.M.Doherty, R.Kastelein, S.Menon, S.Andrade, R.L.Coffman. Modulation of murine macrophage function by IL-13. J Immunol. 1993;151(12):7151–60.
202. D.J.Matthews, C.L.Emson, G.J.McKenzie, H.E.Jolin, J.M.Blackwell, A.N.McKenzie. IL-13 Is a susceptibility factor for Leishmania major infection. J Immunol. 2000;164(3):1458–62.10.4049/jimmunol.164.3.1458
203. M.Saura, R.Martinez-Dalmau, A.Minty, D.Perez-Sala, S.Lamas. Interleukin-13 inhibits inducible nitric oxide synthase expression in human mesangial cells. Biochem J. 1996;313(2):641–6.10.1042/bj3130641
204. E.Bourreau, G.Prévot, R.Pradinaud, P.Launois. Interleukin (IL)–13 Is the predominant Th2 cytokine in localized cutaneous Leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis. 2001;183(6):953–9.10.1086/jid.2001.183.issue-6
205. M.R.Sosa, L.E.Rosas, A.N.McKenzie, A.R.Satoskar. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur J Immunol. 2001;31(11):3255–60.10.1002/(ISSN)1521-4141
206. G.Hansen, J.J.McIntire, V.P.Yeung, G.Berry, G.J.Thorbecke, L.Chen,. CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 2000; 105(1):61–7.
207. G.R.Grotendorst, G.Smale, D.Pencev. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cell Physiol. 1989;140(2):396–402.10.1002/(ISSN)1097-4652
208. D.Q.Tran. TGF-β:the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Cell Mol Biol. 2012; 4(1):29–37.
209. L.Gorelik, R.A.Flavell. Transforming growth factor-[beta] in T-cell biology. Nat Rev Immunol. 2002;2(1):46–53.10.1038/nri704
210. S.Speck, J.Lim, S.Shelake, M.Matka, J.Stoddard, A.Farr,. TGF-β signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PLoS ONE. 2014;9(7):e102390.10.1371/journal.pone.0102390
211. S.Huber, C.Schramm. TGF-beta and CD4+CD25+ regulatory T cells. Front Biosci. 2006;11:1014–23.10.2741/1859
212. S.Fu, N.Zhang, A.C.Yopp, D.Chen, M.Mao, D.Chen,. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 – precursors. Am J Transplant. 2004;4(10):1614–27.10.1111/ajt.2004.4.issue-10
213. Y.Laouar, F.S.Sutterwala, L.Gorelik, R.A.Flavell. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol. 2005;6(6):600–07.10.1038/ni1197
214. P.J.Lucas, S.J.Kim, S.J.Melby, R.E.Gress. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med. 2000;191(7):1187–96.10.1084/jem.191.7.1187
215. A.Nakao, S.Miike, M.Hatano, K.Okumura, T.Tokuhisa, C.Ra,. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 2000;192(2):151–8.10.1084/jem.192.2.151
216. L.Gorelik, P.E.Fields, R.A.Flavell. Cutting edge:TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 2000;165(9):4773–7.10.4049/jimmunol.165.9.4773
217. S.Sad, T.R.Mosmann. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol. 1994;153(8):3514–22.
218. S.M.Wahl, D.A.Hunt, H.L.Wong, S.Dougherty, N.McCartney-Francis, L.M.Wahl,. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140(9):3026–32.
219. J.H.Kehrl, L.M.Wakefield, A.B.Roberts, S.Jakowlew, M.Alvarez-Mon, R.Derynck,. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163(5):1037–50.10.1084/jem.163.5.1037
220. W.Chen, W.Jin, N.Hardegen, K.J.Lei, L.Li, N.Marinos,. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–86.10.1084/jem.20030152
221. M.M.Shull, I.Ormsby, A.B.Kier, S.Pawlowski, R.J.Diebold, M.Yin,. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359(6397):693–9.10.1038/359693a0
222. M.O.Li, S.Sanjabi, R.A.Flavell. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25(3):455–71.10.1016/j.immuni.2006.07.011
223. J.C.Marie, J.J.Letterio, M.Gavin, A.Y.Rudensky. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201(7):1061–7.10.1084/jem.20042276
224. A.Barral, M.Teixeira, P.Reis, V.Vinhas, J.Costa, H.Lessa,. Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Path. 1995;147(4):947–54.
225. L.Kedzierski, K.J.Evans. Immune responses during cutaneous and visceral leishmaniasis. Parasitology. 2014;141(12):1–19.
226. L.Gorelik, S.Constant, R.A.Flavell. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002;195(11):1499–505.10.1084/jem.20012076
227. A.Barral, M.Teixeira, P.Reis, V.Vinhas, J.Costa, H.Lessa,. Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol. 1995;147(4):947–54.
228. M.Barral-Netto, A.Barral. Transforming growth factor-beta in tegumentary leishmaniasis. Braz J Med Biol Res. 1994;27(1):1–9.
229. A.Barral, M.Barral-Netto, E.C.Yong, C.E.Brownell, D.R.Twardzik, S.G.Reed. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A. 1993;90(8):3442–6.10.1073/pnas.90.8.3442
230. J.Li, C.A.Hunter, J.P.Farrell. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol. 1999;162(2):974–9.
231. P.C.Melby, F.J.Andrade-Narvaez, B.J.Darnell, G.Valencia-Pacheco, V.V.Tryon, A.Palomo-Cetina. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 1994;62(3):837–42.
232. N.L.Diaz, O.Zerpa, L.V.Ponce, J.Convit, A.J.Rondon, F.J.Tapia. Intermediate or chronic cutaneous leishmaniasis:leukocyte immunophenotypes and cytokine characterisation of the lesion. Exp Dermatol. 2002;11(1):34–41.10.1034/j.1600-0625.2002.110104.x
233. S.Hejazi, S.Hoseini, S.Javanmard, S.Zarkesh, A.Khamesipour. Interleukin-10 and transforming growth factor-beta in early and late lesions of patients with Leishmania major induced cutaneous Leishmaniasis. Iran J Parasitol. 2012;7(2):53–60.
234. S.Tsunawaki, M.Sporn, A.Ding, C.Nathan. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988;334(6179):260–2.10.1038/334260a0
235. H.Takaki, Y.Minoda, K.Koga, G.Takaesu, A.Yoshimura, T.Kobayashi. TGF-β1 suppresses IFN-γ-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Gene Cell. 2006;11(8):871–82.10.1111/gtc.2006.11.issue-8
236. E.Volpe, N.Servant, R.Zollinger, S.I.Bogiatzi, P.Hupé, E.Barillot,. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol. 2008;9(6):650–7.10.1038/ni.1613
237. S.Nylén, L.Eidsmo. Tissue damage and immunity in cutaneous leishmaniasis. Parasit Immunol. 2012;34(12):551–61.10.1111/pim.12007